Sentences with phrase «current price of our shares»

(You can find a company's market cap by multiplying the number of outstanding shares it has by the current price of each share.)

The S&P / TSX Capped REIT Index is capitalization - weighted, meaning that companies occupy a share of the index proportional to their size (as measured by the current price of a share multiplied by the number or shares outstanding).

The «Price to Earnings» ratio is the current price of the share divided by the company's earnings per share.

To work out a P / E ratio, the current price of the share is divided by the earnings per share (EPS).

Considering the current price of the shares is $ 23, this means an original investment of $ 5,000 has turned into $ 6,857.11.

What I am trying to understand is: If we know the number of shares a company trades and the current price of the share, can we estimate what volume of trade that is required to move the share price in either direction?

If the price of Company X's shares rises and you close out your CFD, the seller of the CFD (the counterparty) will pay you the difference between the current price of the shares and the price when you took out the contract.

On the last earnings call he told investors, «We continue to believe there is an absolute disconnect between our current price of our shares relative to the value and performance of our portfolio.

Not exact matches

T. Rowe dropped Dropbox shares by 16 percent, meaning the current value of its holdings in that company is reportedly under water — 13 percent below the firm's original purchase price in 2012.

The Instagram story also shows that she was given 995 Adidas (addyy) shares, which would also have a total value of around $ 100,000 at current prices.

Gerstner said he thinks United Airlines stock is worth double or triple its current share price of about $ 75, or even more, with his target price at as much as $ 235 a share.

The lot size rule for Japan shares makes it hard for Nintendo to widen the base of investors at the current price, says Atul Goyal of Jefferies.

Corey Davis, an analyst with investment firm Jefferies & Co., estimates shares will rise to $ 1.44 in 2014 (about a 60 cents jump from the current price) after the combined company has a full year of operations under its belt.

Similarly, the volume simply converted based on the current share price is expected to reach a total of 2.37 million shares consisting of the existing 1.61 million ordinary shares (2.04 million before division) and 0.76 million shares to be additionally purchased and retired.

For instance, a company may give an employee the right to buy 100 shares at the current price of $ 10 per share in 1998.

HelloFresh sold 31 million new shares in an initial public offering, giving it a valuation around 1.7 billion euros at current prices — more than double the $ 888 million (763 million euro) market capitalization of struggling Blue Apron (aprn).

The stock has been a Wall Street whirlwind since its late January 2015 IPO, initially surging more than 100 percent to $ 96.75 a share, only to fall nearly 50 percent to its current price of around $ 49.

Still, Fitbit has something of a first - mover advantage that's likely to keep its share price floating at its current level of around $ 32, which is more than 40 percent higher than its trading start price.

Wells Fargo downgraded the company to market underperform, and put a price target of $ 7 a share on it, over a buck above its current price — always lagging behind, always keeping that optimism going.

Microsoft's share price is also a good arbiter of that decision to stay the course in PCs, and an inability to get current.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

To calculate a company's market capitalization, multiply its current share price by its number of outstanding shares.

Examples of such projects providing marginal benefits are: improving financial reporting systems through better information technology, minor tweaks to supply chain logistics, cutting back on marketing or increasing low - cost advertising (like social media), «rationalization» of head count, holding average wages as low as possible, squeezing suppliers a little bit, not repatriating earnings to stave off taxation, refinancing rather than retiring debts, and the share buyback that is insensitive to a company's current stock price.

The second rule of thumb relates to our current fuel derivative portfolio where a 10 % reduction in the price of Brent for the remaining half of 2012 would result in an additional $ 0.04 of realized losses on fuel derivatives that would offset the $ 0.13 per share favorable impact from the reduced price of fuel.

Using our current fuel price of $ 620 per metric ton, we are currently estimating that lower fuel prices should benefit first half 2013 earnings per share by approximately $ 0.23.

With virtually identical market capitalization (the price it would take to buy all shares of a company's outstanding common stock at the current market value), what exactly is an investor in each respective firm getting for his or her money?

The company in August sold 1.5 million unregistered shares to a private investor who is also a current shareholder at a price of $ 2.10 per share, for aggregate consideration of $ 3.15 million.

At its current price of $ 55 / share, HLF has a price to economic book value (PEBV) ratio of 1.4.

At its current valuation of ~ $ 67 / share, HLF has a price to economic book value ratio (price - to - EBV) of 1.2 That ratio means that the market expects only 20 % growth in NOPAT for the remainder of HLF's existence.

Moreover, as home prices rose, household net worth increased, making households more willing to consume a greater share of their current income.

THL Credit pays quarterly dividends of $ 0.27 per share, giving TCRD stock a staggering annual yield of 13.8 % at the current price.

In order to justify its current price of $ 31 / share, the company would need to grow NOPAT by 15 % compounded annually for the next 5 years.

To justify the current price of $ 47 / share, Jarden must grow NOPAT by 13 % compounded annually for the next 16 years, at which point, Jarden would be generating over $ 66 billion in revenue.

The billionaire investor, 79, held 1.41 million Netflix shares as of March 31, according to data compiled by Bloomberg, making the latest sales worth about $ 960 million at current prices.

This ratio is calculated by dividing the current Price by the sum of the Basic Earnings Per Share from continuing operations BEFORE Extraordinary Items and Accounting Changes over the last four quarters.

At its current price of $ 105 / share, HAS has a price - to - economic book value (PEBV) ratio of 1.2.

Price - to - Earnings (P / E) Ratio The ratio of a company's current share price to its reported earnPrice - to - Earnings (P / E) Ratio The ratio of a company's current share price to its reported earnprice to its reported earnings.

At its current price of $ 142 / share, CLX has a price - to - economic book value (PEBV) ratio of 1.2.

The ratio of a company's current share price to reported sales.

The current value of shares is determined by multiplying the number of shares by their highest current public offering price.

Through these schemes, Shkreli obtained over $ 5.6 million in cash and Retrophin shares or the use of Retrophin shares worth over $ 59 million (at current market prices).

One important metric used is the price - to - earnings ratio, or, the current price of the stock divided by the average earnings per share (yearly revenue divided by the number of outstanding shares).

Despite the impressive fundamentals, at its current price of $ 66 / share, Wal - Mart has a PEBV ratio of 0.8.

As a result of these agreements, Retrophin paid $ 200,000 in cash and issued 581,000 shares to MSMB investors, resulting in a benefit to Shkreli of over $ 17.3 million (at current market prices), and is embroiled in an arbitration with Rosenfeld in which Rosenfeld is seeking $ 1,650,000.

The consortium of buyers have about four weeks to lock in enough investors at the current share price or to offer a higher price.

Best of all, at its current price of $ 35 / share, Oracle has a price - to - economic book value (PEBV) ratio of 0.9.

(f) by causing Retrophin to enter into the Yaffe Consulting Agreement, as a result of which Retrophin paid $ 200,000 in cash and issued 15,000 shares to Yaffe, resulting in a benefit to Shkreli of more than $ 600,000 (at current market prices).

As a result of these agreements, Retrophin paid out $ 2.8 million in cash and issued 11,000 Retrophin shares, and Shkreli diverted an additional 47,610 Retrophin shares for the benefit of himself and his MSMB Funds, resulting in a benefit to him and to them of more than $ 4.5 million (at current market prices).1

(i) by causing Retrophin to commence a litigation against Doe in order to coerce Doe into giving Shkreli Doe's Fearnow Shares, and by causing Retrophin to enter into a settlement with Doe whereby Retrophin paid $ 100,000 and Doe delivered 50,000 shares to Shkreli, resulting in a benefit to Shkreli of more than $ 1.4 million (at current market prShares, and by causing Retrophin to enter into a settlement with Doe whereby Retrophin paid $ 100,000 and Doe delivered 50,000 shares to Shkreli, resulting in a benefit to Shkreli of more than $ 1.4 million (at current market prshares to Shkreli, resulting in a benefit to Shkreli of more than $ 1.4 million (at current market prices).

(d) by causing Retrophin to pay cash to himself, Biestek, and Fernandez so that he would not have to invest $ 731,778 of his own funds in the February PIPE, and by using PIPE proceeds in contravention of the terms of the Securities Purchase Agreement to fund investments by Shkreli, Biestek and Fernandez, resulting in an additional benefit to Shkreli alone of $ 360,000 in cash and 180,000 Retrophin shares and warrants worth more than $ 5.3 million (at current market prices).